n.a. (CHTP)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech

Biotechnology stocks have been front and center this week amidst the J.P. Morgan Healthcare conference, the big conference held in San Francisco each January where so many companies reveal important outlooks for the year and important pipeline updates. Historically, biotechnology stocks have outperformed during this conference week -- and we have seen broad-based strength from the group -- but more importantly, investors are provided with a reiteration of some of the strong themes that will dominate 2014...

A Few Minutes With Chelsea's CEO on Tuesday's Northera Panel and Future Plans

A Few Minutes With Chelsea's CEO on Tuesday's Northera Panel and Future Plans

Chelsea CEO Joe Olivetto is confident about Northera heading into the Feb. 14 FDA approval data following the positive recommendation from Tuesday's panel.

Chelsea Therapeutics: Northera FDA Panel Live Blog

Chelsea Therapeutics: Northera FDA Panel Live Blog

A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.

Chelsea Blues: FDA Reviewer Hates Northera But Don't Head For Exit Quite Yet (Corrected)

Chelsea Blues: FDA Reviewer Hates Northera But Don't Head For Exit Quite Yet (Corrected)

The FDA posted a very harsh medical review of Chelsea Therapeutics' Northera ahead of Tuesday's advisory panel meeting. Chelsea shares are taking a beating Friday morning.

Try These Picks, but Don't Fall in Love

Here are some areas of the global markets to watch closely in 2014.

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

Biotech Stock Mailbag: Inovio, Chelsea, Exelixis, Ariad, ImmunoCellular

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

Accuray: From Innovation to Profitability

The transition from research to sales is hard for some biotech firms.

Buy a Risky Stock to Reduce Risk

With Chelsea Therapeutics, more equals less.

2014 FDA Drug Approval Decision Calendar

2014 FDA Drug Approval Decision Calendar

Here's a list of 34 FDA drug approval decisions and scheduled advisory panels from December 31 through October 2014.

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Biotech Stock Mailbag: Enanta, Vanda, Pharmacyclics, Top 2014 Stock Catalysts

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

January 2014 Options Now Available For Chelsea Therapeutics International (CHTP)

January 2014 Options Now Available For Chelsea Therapeutics International (CHTP)

Investors in Chelsea Therapeutics International Ltd saw new options become available today, for the January 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 75 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stock Mailbag: Chelsea's FDA Panel, Ariad's Future, Bio-Bubble Update

Biotech Stock Mailbag: Chelsea's FDA Panel, Ariad's Future, Bio-Bubble Update

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Biotech Stocks Under $10 for Your Watch List

5 Biotech Stocks Under $10 for Your Watch List

Keep an eye on these under-$10 biotech stocks.

First Week Of June 2014 Options Trading For Chelsea Therapeutics International (CHTP)

First Week Of June 2014 Options Trading For Chelsea Therapeutics International (CHTP)

Investors in Chelsea Therapeutics International Ltd saw new options begin trading this week, for the June 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Chelsea Therapeutics Announces FDA Advisory Committee To Review NORTHERA(TM) (droxidopa)

Chelsea Therapeutics Announces FDA Advisory Committee To Review NORTHERA(TM) (droxidopa)

Panel Date Tentatively Set for January 14, 2014

4 Biotech Stocks Under $10 on the Verge of Breakouts

4 Biotech Stocks Under $10 on the Verge of Breakouts

Keep these under-$10 biotech stocks on your radar.

Chelsea Therapeutics Announces FDA Acceptance Of NORTHERA(TM) (droxidopa) NDA Resubmission

Chelsea Therapeutics Announces FDA Acceptance Of NORTHERA(TM) (droxidopa) NDA Resubmission

FDA Deems Resubmission a Complete Response; PDUFA Date Set as February 14, 2014

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.